Pédiatrie Sarcomes CombinaiR3 First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years Paris VALERIE LAURENCE
Pédiatrie Hématologie EURONET-PHL-C2 European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents Paris
Pédiatrie Sarcomes SARCOME 13 (Pédiatrie) Multicentre, Randomised, Phase 2 Trial of Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients (Metastatic Osteosarcoma at Diagnosis or Localised Disease With Poor Histological Response) Paris HELENE PACQUEMENT
Pédiatrie Sarcomes E7080-G000-230 OLIE A Multicenter, Open-label, Randomized Phase 2 Study to Compare the Efficacy and Safety of;Lenvatinib in Combination with Ifosfamide and Etoposide versus Ifosfamide and Etoposide in;Children, Adolescents and Young Adults with Relapsed or Refractory Osteosarcoma Paris ISABELLE AERTS
Pédiatrie Neuroblastomes J1O-MC-JZHD A Phase 1 Study of;Aurora Kinase A Inhibitor LY3295668 erbumine as a Single;Agent and in Combination in Patients with;Relapsed/Refractory Neuroblastoma Paris ISABELLE AERTS
Sarcomes J1S-MC-JV01 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Paris SOPHIE PIPERNO-NEUMANN
Sarcomes J1S-MC-JV02 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma Paris SOPHIE PIPERNO-NEUMANN
Pédiatrie Neuroblastomes EUSA-PASS (EUSA-DB-0001) A Post-Authorisation Safety Study Patient Registry of Patients With High-risk Neuroblastoma Being Treated With the Monoclonal Antibody Dinutuximab Beta Paris GUDRUN SCHLEIERMACHER
Pédiatrie Sarcomes ZN-c3-003 A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma Paris ISABELLE AERTS
Pédiatrie Sarcomes COTESARC (pédiatrie) multicentre, open-label, Phase I-II study evaluating the combination of a MEK inhibitor and a PDL1 inhibitor in pediatric and adult patients with locally advanced and/or metastatic soft tissue sarcoma Paris ISABELLE AERTS